CD274 and non-small cell lung carcinoma: Among the emerging therapies, immune checkpoint inhibitors (ICIs), such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies, have shown great promise in the treatment of various malignancies including melanoma, non-small-cell lung cancer (NSCLC), and renal-cell cancer [1, 2].